BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial

被引：55

作者：

Siu, Lillian L.

Gelmon, Karen

Chu, Quincy

Pachynski, Russell

Alese, Olatunji

Basciano, Paul

Walker, Justine

Mitra, Priyam

Zhu, Li

Phillips, Penny

Hunt, John

Desai, Jayesh

机构：

来源：

关键词：

D O I：

10.1158/1538-7445.AM2017-CT116

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT116

引用

页数：2